What is Fios Genomics?
Fios Genomics operates at the critical intersection of computational biology and pharmaceutical research. The company provides specialized bioinformatics data analysis services, transforming complex biological datasets into actionable insights. Their core competencies include gene expression analysis, single-cell sequencing, and proteomics, all of which are essential for accelerating drug discovery and validating research findings. By serving as a strategic partner to pharmaceutical companies and CROs, Fios Genomics bridges the gap between raw data generation and clinical application. Furthermore, the firm distinguishes itself through a commitment to sustainability, evidenced by its status as an SME Climate Hub member, aligning its technical operations with broader environmental responsibility goals.
How much funding has Fios Genomics raised?
Fios Genomics has raised a total of $2.8M across 4 funding rounds:
Private Equity
$817K
Series B
$710K
Other Financing Round
$795K
Series C
$509K
Private Equity (2011): $817K with participation from Archangel Informal Investment and Scottish Enterprise
Series B (2011): $710K led by TRICAPITAL and Archangels
Other Financing Round (2013): $795K supported by Tweed Renaissance Investors Capital and Archangel
Series C (2014): $509K featuring Tweed Renaissance Investors Capital
Key Investors in Fios Genomics
Tweed Renaissance Investors Capital
Tweed Renaissance Investors Capital (TRI Cap) is a business angel syndicate based in the Scottish Borders, with the intention of investing in growth businesses in the Borders and beyond. Its founders include some of the Borders' leading business people who, between them, have many years' experience of building and investing in enterprises in the Borders and further afield.
Scottish Enterprise
Founded in 1991, Scottish Enterprise is headquartered in Glasgow, United Kingdom. They are a national economic development agency and a non-departmental public body of the Scottish Government.
Archangel Informal Investment
Archangel Informal Investment is a prominent Scottish-based syndicate focused on providing early-stage and growth capital to technology-driven enterprises with high scalability potential.
What's next for Fios Genomics?
Looking ahead, Fios Genomics is poised to leverage its recent capital influx to enhance its technological infrastructure and broaden its service portfolio. As the demand for precision medicine and high-throughput data analysis continues to surge, the company is expected to focus on scaling its computational capabilities to handle increasingly complex multi-omics datasets. Strategic priorities likely include the integration of advanced machine learning algorithms to improve predictive accuracy in drug development and the expansion of its collaborative network with global research entities. By maintaining its focus on high-quality, reproducible research outcomes, Fios Genomics is set to remain a pivotal player in the life sciences ecosystem, driving innovation through data-driven decision-making and sustainable business practices.
See full Fios Genomics company page
